-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Editor: Traveler
Yimaitong edited and sorted, please do not reprint
without authorization.
The 25th National Congress of Clinical Oncology and the 2022 CSCO Annual Conference were held
from November 5th to 12th.
The theme of this conference is "Precision Innovation, Intelligent Humanities", the conference focuses on the clinical frontier of oncology, joins hands with experts and scholars in the field of oncology across the country, shares clinical research and innovation results, and strives to comprehensively and accurately reflect new concepts and new trends
in the field of clinical oncology.
During the conference, Yimaitong was honored to invite Professor
Yimaitong: Systemic therapy represented by immunity and targeted drugs has brought important changes to the treatment of liver cancer, how to view the development direction of systemic treatment of liver cancer, and what are the challenges?
Professor Liang Jun: Systematic treatment is an indispensable part of multidisciplinary diagnosis and treatment of liver cancer, and the survival of liver cancer patients in the early chemotherapy era is generally poor, and later the application of tyrosine kinase inhibitors (TKI) such as sorafenib,
for the systematic treatment of liver cancer.
While TKI has played an important role, immunotherapy has gradually entered the stage
of systemic therapy.
A number of blockbuster studies such as IMbrave-150, ORIANT-32 and SHR-1210-III-310 have established the importance of immunotherapy in the treatment of liver cancer, and the studies used atezolizumab + bevacizumab regimen, "Shuangda" regimen (
in the future.
Of course, while seeing the bright future, we cannot ignore the challenges
of immunotherapy.
In the past, several immunotherapy-related studies have not achieved positive results, and we have achieved today's success on the basis of previous exploration, but the problems of primary drug resistance in first-line treatment and specific choices of second-line treatment still need to be solved
.
Therefore, we should conduct more in-depth clinical exploration in this field to provide more opportunities for patients to cure
.
Yimaitong: Local treatment such as intervention, radiofrequency ablation, radiotherapy is an important means of liver cancer treatment, how do you see the prospect of systemic therapy and local therapy combined treatment for liver cancer?
Professor Liang Jun: Local treatment includes radiotherapy, hepatic arterial perfusion chemotherapy (HAIC) and hepatic arterial chemoembolization (TACE), etc.
, in the treatment of liver cancer, the status, role and survival benefits of local therapy cannot be ignored
.
However, there are also some bottlenecks in local treatment, and liver cancer patients will have a certain degree of damage to liver function after multiple local treatments, which will affect the patient's organ function and even survival prognosis
.
In addition, liver cancer is not completely confined to the liver, and the efficacy of local treatment is extremely limited
for patients with liver cancer with lung metastases or other metastases.
In this case, the importance of topical therapy combined with systemic therapy is self-evident, and the two therapies can control both local lesions and systemic metastases at the same time
.
In addition, studies on the mechanism of action suggest that local therapy and systemic therapy can synergistically exert anti-cancer effects
.
For example, in the combination of radiotherapy and immunotherapy, radiotherapy can promote the release of tumor antigens, while immunotherapy can capture tumor antigens, so the combination of the two can maximize the efficacy
.
All in all, whether it is the mechanism of action or the actual exploration, local therapy combined with systemic therapy has a very good application prospect
in liver cancer.
